The FDA Has Accepted For Review Takeda's New Drug Application Resubmission For TAK-721 (Budesonide Oral Suspension) For The Short-term Treatment Of Eosinophilic Esophagitis
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Takeda's resubmission of its New Drug Application for TAK-721 (Budesonide Oral Suspension) for the short-term treatment of Eosinophilic Esophagitis.
September 20, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Takeda's New Drug Application for TAK-721 has been accepted by the FDA, potentially leading to a new revenue stream if the drug is approved.
The FDA's acceptance of Takeda's New Drug Application for TAK-721 is a positive development for the company. If the drug is approved, it could open up a new revenue stream for Takeda. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100